Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mereo BioPharma
Biotech
Amgen weaves in UK biotech with up to $840M acquisition
Amgen has stitched together a deal worth up to $840 million for Dark Blue Therapeutics, a private biotech in Oxford.
Gabrielle Masson
Jan 6, 2026 10:35am
Ultragenyx plans cost-cutting push after flunking phase 3 trials
Jan 2, 2026 5:37am
Lack of early win for Ultragenyx’s bone disorder med dents stock
Jul 10, 2025 8:04am
Ultragenyx, Mereo's brittle bone drug sustains fracture rate cut
Jun 12, 2024 8:55am
Ultragenyx, Mereo's bone disease med cuts fractures by 67%
Oct 16, 2023 12:39pm
Ultragenyx brittle bone drug causes fast improvements in phase 2
Jun 6, 2023 7:42am
